• Spinal biologics market to hit $2.3B by 2027: 5 notes

    The global spinal biologics industry is projected to reach $2.3 billion by 2027, growing at a compound annual growth rate of 2.8 percent, according to ReportLinker.com.
  • KICVentures Group acquires NanoFuse Biologics

    Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics.
  • Novartis' spinal muscular atrophy drug approved in Canada

    Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA.
  • N2 Biomedical appoints new CEO

    Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release.

Featured Webinars

Featured Whitepapers